Back to results
US 2014/0193908 A1Published application
Sequential antibody therapy
AssigneePhilogen S.P.A.
InventorKathrin Schwager
Life of this patent
Estimating the term…
Abstract
The invention provides a blocking ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex, for sequential use in inhibiting the growth of tumour cell
Claims16
A method for inhibiting the growth of a tumour cell comprising contacting said cell with a ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex.
(canceled)
Dependencies are inferred from the claim text.